Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;6(Suppl 1):S62-S66.
doi: 10.21037/tlcr.2017.10.10.

Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer

Chong-Kin Liam  1
Affiliations
Editorial

Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer

Chong-Kin Liam. Transl Lung Cancer Res. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Comment on

References

    1. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v1-27. 10.1093/annonc/mdw326 - DOI - PubMed
    1. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer (version 8.2017). accessed on September 23, 2017. Available online: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
    1. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17:1616-22. 10.1158/1078-0432.CCR-10-2692 - DOI - PMC - PubMed
    1. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-7. 10.1158/1078-0432.CCR-12-2246 - DOI - PMC - PubMed
    1. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046-61. 10.1158/2159-8290.CD-14-0337 - DOI - PMC - PubMed